Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer

Sponsor
National Cancer Center, Korea
Study ID
NCT00506571
Phase
PHASE2
Status
Unknown

Conditions

  • Colorecal Neoplasms
  • Secondary

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Patients will be treated with irinotecan (150 mg/m2) followed by oxaliplatin (85 mg/m2) on day 1 and S-1 (80 mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy. Response assessment will be performed every 2 cycles of chemotherapy.

Key Dates

Start date
Jul 31, 2007
Status verified
Apr 2007
Completion
Jun 30, 2010

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Maximal overall response rate [ Time Frame: During chemotherapy ]

Central Contacts